Jiangxi Fushine Pharmaceutical Co Ltd (300497) — Strategic Asset Allocation Index
Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a Strategic Asset Allocation Index of 87.1% as of June 2023. Strategic assets (PP&E of CN¥2.29 Billion plus long-term investments of CN¥-) total CN¥2.29 Billion, measured against net assets of CN¥2.62 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Jiangxi Fushine Pharmaceutical Co Ltd Strategic Asset Allocation Index (2011–2022)
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 12 annual periods from 2011 to 2022. As of June 2023, the index stands at 87.1%, representing strategic assets of CN¥2.29 Billion against net assets of CN¥2.62 Billion CNY. Explore Jiangxi Fushine Pharmaceutical Co Ltd (300497) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2022, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Jiangxi Fushine Pharmaceutical Co Ltd.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 81.8% | CN¥2.20 Billion | CN¥2.20 Billion | CN¥- | CN¥2.69 Billion | ▲ +18.0 pp |
| 2021 | 63.8% | CN¥1.86 Billion | CN¥1.86 Billion | CN¥- | CN¥2.91 Billion | ▲ +24.5 pp |
| 2020 | 39.3% | CN¥1.20 Billion | CN¥1.20 Billion | CN¥- | CN¥3.05 Billion | ▼ -19.9 pp |
| 2019 | 59.2% | CN¥904.19 Million | CN¥904.19 Million | CN¥- | CN¥1.53 Billion | ▼ -10.6 pp |
| 2018 | 69.8% | CN¥800.26 Million | CN¥662.75 Million | CN¥137.51 Million | CN¥1.15 Billion | ▲ +2.3 pp |
| 2017 | 67.5% | CN¥652.06 Million | CN¥508.10 Million | CN¥143.96 Million | CN¥966.71 Million | ▲ +11.8 pp |
| 2016 | 55.7% | CN¥436.64 Million | CN¥422.68 Million | CN¥13.96 Million | CN¥784.17 Million | ▲ +3.2 pp |
| 2015 | 52.5% | CN¥313.09 Million | CN¥303.13 Million | CN¥9.96 Million | CN¥596.21 Million | ▼ -36.8 pp |
| 2014 | 89.3% | CN¥252.91 Million | CN¥252.91 Million | CN¥- | CN¥283.26 Million | ▼ -6.1 pp |
| 2013 | 95.4% | CN¥219.13 Million | CN¥219.13 Million | CN¥- | CN¥229.76 Million | ▲ +4.9 pp |
| 2012 | 90.4% | CN¥166.93 Million | CN¥166.93 Million | CN¥- | CN¥184.60 Million | ▲ +11.0 pp |
| 2011 | 79.4% | CN¥95.67 Million | CN¥95.67 Million | CN¥- | CN¥120.52 Million | — |